FIRST QUARTER 2025 RESULTS

Milan, May 8th 2025

RECORDATI

SPEAKERS

Rob Koremans
Chief Executive Officer

Luigi La Corte
Chief Financial Officer

Q1 2025: STRONG START TO THE YEAR ACROSS THE BUSINESS

- **Q1 2025 results** show a strong start of the year, with **Net Revenue at € 680.0 million, +11.9% vs PY or 7.2% like-for-like[1] at CER;** adverse FX impact of € 3.7 million (-0.6%), mostly from Turkish lira, offset by price inflation:
  - **SPC at € 408.6 million**, **+3.3% vs PY** or **+5.0% at CER** (+2.3% ex Türkiye) vs a robust Q1 2024 driven by strong growth across all core therapeutic areas offsetting softer Cough & Cold, due to weaker flu season in Russia and Türkiye
  - **RRD at € 254.8 million**, **+29.0% vs PY** or **+11.5% like-for-like[1] at CER,** driven by continued strength of Endocrinology +18.0%, Hema-Oncology +64.3% vs PY, or +9.6% like-for-like[1] (Enjaymo® contribution of € 31.9 million); Metabolic returning to growth
- **EBITDA[2]** of **€ 270.2 million, +10.7% vs PY or 39.7% margin** reflecting strong revenue performance partially offset by slightly higher investments ahead of the recent expanded approval of Isturisa® for Cushing's syndrome in the U.S. and for continued geographic expansion
- **Adjusted Net Income[3]** of **€ 175.5 million, +7.2% vs PY or 25.8% margin**, thanks to higher operating income partially offset by increased financial expenses and higher tax rate
- **Free Cash Flow[4]** of **€ 158.8 million** (+€ 11.7 million vs PY) driven by higher EBITDA offset by working capital growth (in line with revenue) and interest paid; **leverage at just below 2.2x EBITDA pro-forma[5]**
- **R&D updates**: **Isturisa®** (osilodrostat) granted expanded FDA approval for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome, supporting peak year sales raise to € 550-650 million; **Signifor® LAR approved in China** for the treatment of acromegaly (following prior approvals in China for Isturisa® and Carbaglu®)
- **FY 2025 guidance confirmed** (despite increased FX headwinds), and positive momentum expected to continue, as reflected in the **FY 2027 financial targets** approved on April 28th, with **double-digit growth across all key metrics**

1) Pro-forma growth calculated excluding revenue of Enjaymo® for Q1 2025
2) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3
3) Net income excluding amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3, monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.
4) Total cash flow excluding financing items, milestones, dividends, purchases of treasury shares net of proceeds from exercise of stock options
5) Pro-forma calculated by adding Enjaymo's® estimated contribution from April to November 2024 (when it still was propriety of Sanofi) to EBITDA

SPECIALTY & PRIMARY CARE: RESILIENT MID-SINGLE DIGIT GROWTH AT CER DESPITE WEAKER C&C SEASON

Pharmaceutical Revenue Q1 2025 vs Q1 2024[1]



1) Excluding Chemicals € 16.5 million in Q1 2025 and € 14.8 million in Q1 2024
2) IQVIA February YTD Evolution Index on promoted products in SPC territories excluding Avodart/Combodart
3) Trademarks are owned by or licensed to the GSK group of companies.
Note: details on corporate products in Appendix

Key highlights

- **Resilient growth of +3.3% or +5.0% at CER** (+2.3% excluding Türkiye) vs strong Q1 2024, **continued overperformance of promoted portfolio** vs relevant markets (just over 105% Evolution Index[2])
- **Urology**: Stable contribution of Eligard® vs very strong Q1 2024 due to rollout of new device, strong growth of **Urorec®** (mainly in Russia, Italy and Türkiye) and **regional products** (Tergynan® in Russia and Mictonorm® in Türkiye), partially offset by a decline of Avodart®/Combodart®, mainly due to Gx pressure in Spain
- **Cardiovascular:** Steady growth of **lercanidipine** across geographies and **metoprolol** in CEE
- **Gastrointestinal:** Driven by double-digit growth of **Procto Glyvenol®** and **Salaza®** in Poland (benefiting from withdrawal of competitor)
- **Cough & Cold:** Weak C&C season (Russia and Türkiye) against a favorable phasing of shipments in Q1 2024; expect some recovery over balance of the year

RARE DISEASES: DOUBLE-DIGIT GROWTH DRIVEN BY ALL FRANCHISES

Revenue Q1 2025 vs Q1 2024

million Euro



Key highlights

- Strong double-digit growth, **+29.0% vs PY or 11.5%** like-for-like[2] at CER **driven by all franchises**
- **Endocrinology:**
  - **Isturisa®:** Double-digit growth driven mostly by continued new patient uptake across all key geographies; peak year sales raised to € 550-650 million (from € 500-600 million) after recently approved label extension in the U.S.
  - **Signifor®:** Double-digit growth mainly driven by higher volumes in U.S. and EU; Signifor LAR® approved in China
- **Hema-Oncology:** High-single digit growth (+9.6% like-for-like[2]) driven by higher volumes for Sylvant® in U.S. and EMEA which was slightly offset by adverse phasing of shipments of Qarziba®. Sales of Enjaymo® were € 31.9 million (+16.2% vs Q1 2024 pro-forma[3]), in line with plan
- **Metabolic:** Return to growth driven by strong performance of Panhematin® in U.S. and Carbaglu® in South America (also reflecting positive phasing)

1) *Of which Isturisa® of € 55.0 million and Signifor® and Signifor® LAR of € 32.4 million*
2) *Proforma growth calculated excluding contribution of Enjaymo® for 2025*
3) *Comparing Q1 2025 revenue (which considers also the margin retained by Sanofi's in market sales for those countries where it was still holding the MA) with Q1 2024 revenue realized in total by Sanofi*

CONTINUED ROBUST GROWTH ACROSS ALL REGIONS

(million euro)	Q1 2025	Q1 2024	Change %
U.S.A.	**121.1**	90.0	*34.7*
Italy	**94.8**	89.8	*5.6*
Spain	**55.2**	52.6	*4.8*
France	**46.4**	46.0	*1.0*
Germany	**44.3**	41.5	*6.7*
Russia, other CIS countries and Ukraine	**42.1**	41.2	*2.2*
Türkiye	**42.2**	37.3	*13.1*
Portugal	**17.7**	16.1	*10.3*
Other C.E.E. countries	**49.0**	41.4	*18.4*
Other W. European countries	**40.7**	39.8	*2.2*
North Africa	**14.9**	12.7	*16.9*
Other international sales	**95.2**	84.7	*12.4*
TOTAL PHARMACEUTICALS	**663.4**	593.0	*11.9*
CHEMICALS	**16.5**	14.8	*11.4*

in local currency, million	Q1 2025	Q1 2024	Change %
U.S.A. (USD)	**127.5**	97.7	*30.5*
Türkiye (TRY)	**1,648.1**	1,249.9	*31.9*
Russia (RUB)[1]	**2,597.3**	2,489.8	*4.3*

1) Net revenue in local currency in Russia exclude sales of products for rare diseases

STRONG REVENUE GROWTH SUSTAINS EBITDA MARGIN AT ~40%

(million Euro)	Q1 2025	Q1 2024	*Change %*
Revenue	**680.0**	**607.8**	*11.9*
Gross Profit	**458.8**	**415.6**	*10.4*
as % of revenue	67.5%	68.4%	
Adjusted Gross Profit[1]	**481.2**	**429.9**	*11.9*
as % of revenue	70.8%	70.7%	
SG&A Expenses	181.4	156.5	*15.9*
as % of revenue	26.7%	25.7%	
R&D Expenses	80.1	67.3	*19.0*
as % of revenue	11.8%	11.1%	
Other Income (Expense), net	(1.5)	(4.9)	*(69.3)*
as % of revenue	(0.2%)	(0.8%)	
Operating Income	**195.8**	**186.9**	*4.7*
as % of revenue	28.8%	30.7%	
Adjusted Operating Income[2]	**219.2**	**202.0**	*8.5*
as % of revenue	32.2%	33.2%	
Financial income/(Expenses), net	(30.9)	(25.7)	*20.0*
as % of revenue	(4.5%)	(4.2%)	
Net Income	**125.0**	**123.6**	*1.2*
as % of revenue	18.4%	20.3%	
Adjusted Net Income[3]	**175.5**	**163.7**	*7.2*
as % of revenue	25.8%	26.9%	
EBITDA[4]	**270.2**	**244.0**	*10.7*
as % of revenue	39.7%	40.2%	

1) Gross profit adjusted from impact of non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3
2) Net income before income taxes, financial income and expenses, non-recurring items, and non-cash charges arising from the allocation of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3
3) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3
4) Net income excluding amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3, monetary net gains/losses from hyperinflation (IAS 29), net of tax effects

STRONG FCF GROWTH DRIVEN BY HIGHER EBITDA

(million Euro)	Q1 2025	Q1 2024	*Change*
EBITDA[1]	**270.1**	244.0	*26.1*
Movements in working capital	**(52.3)**	(46.9)	*(6.3)*
Changes in other assets & liabilities	**(12.8)**	(14.9)	*2.1*
Interest received/(paid)	**(31.6)**	(19.4)	*(12.2)*
Income tax Paid	**(12.3)**	(14.3)	*2.0*
Other	**3.6**	1.6	*2.0*
Cash Flow from Operating Activities	**164.7**	151.0	*13.7*
Capex (net of disposals)	**(5.9)**	(3.9)	*(2.0)*
Free cash flow[2]	**158.8**	147.1	*11.7*
Increase in intangible assets (net of disposals)	**(2.4)**	(4.1)	*1.7*
Dividends paid	**(1.1)**	(0.7)	*(0.4)*
Purchase of treasury shares (net of proceeds)	**(24.4)**	4.6	*(29.0)*
Other financing cash flows[3]	**(120.3)**	(74.0)	*(46.3)*
Change in cash and cash equivalents	**10.6**	72.9	*(62.3)*

1) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3
2) Total cash flow excluding financing items, milestones, dividends, purchases of treasury shares net of proceeds from exercise of stock options
3) Opening of financial debts net of repayments and currency translation effect on cash and cash equivalents.

LEVERAGE AT JUST BELOW 2.2x EBITDA PRO-FORMA[1]

(million Euro)	31-Mar-25	31-Dec-24	*Change*
Cash and cash equivalents	**333.0**	322.4	*10.6*
Short-term debts to banks and other lenders	**(20.4)**	(22.8)	*2.4*
Loans and leases - due within one year[2]	**(286.8)**	(284.9)	*(1.9)*
Loans and leases - due after one year[2]	**(2,046.6)**	(2,169.0)	*122.4*
NET FINANCIAL POSITION[3]	**(2,020.8)**	(2,154.3)	*133.5*

1) Pro-forma calculated by adding Enjaymo's® estimated contribution from April to November 2024 (when it still was propriety of Sanofi) to EBITDA.
2) Includes the fair value measurement of the relative currency risk hedging instruments (cash flow hedge)
3) Cash and cash equivalents, less bank debts and loans, which include the measurement at fair value of hedging derivatives

ON TRACK TO DELIVER FY 2025 TARGETS AND SUSTAIN DOUBLE-DIGIT REVENUE AND EBITDA GROWTH TO 2027

million Euro	FY 2024 Actual	FY 2025 Target	FY 2027 Target (incl. BD & M&A)	*CAGR* 2024-2027* (mid-point)
Revenue *yoy growth*	**2,341.6**	**2,600 – 2,670** *+12.5%**	**3,000 – 3,200**	***+9.8%***
EBITDA (1) *margin on sales*	**865.8** *37.0%*	**970 – 1,000** *+/- 37.5%*	**1,140 – 1,225** *≥38%*	***+11.0%***
Adjusted Net Income (2) *margin on sales*	**568.9** *24.3%*	**640 – 670** *+/- 25%*	**770 – 820** *+/- 25.5%*	***+11.8%***

**YoY Growth and CAGR at mid-point of guidance range*

1) *Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3*
2) *Net income excluding amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3, monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.*

QUESTIONS & ANSWERS

Q&A

Rob Koremans
Chief Executive Officer

Luigi La Corte
Chief Financial Officer

Alberto Martinez
Executive VP Specialty
& Primary Care

Scott Pescatore
Executive VP
Rare Diseases

Milan Zdravkovic
Executive VP
Research & Development

APPENDIX

COMPOSITION OF REVENUE

DIVERSIFIED PORTFOLIO AND FOOTPRINT

Therapeutic Areas

Total Revenue Q1 2025



Geographic

Pharmaceutical Revenue Q1 2025



Note: Total OTC of € 101.8 million in Q1 2025 and € 95.5 million in Q1 2024
Subsidiaries' local product portfolios of € 108.2 million in Q1 2025 and € 112.6 million in Q1 2024

MAIN PRODUCT SALES

(million Euro)	Q1 2025	Q1 2024	*Change %*
Specialty & Primary Care	**408.6**	395.5	*3.3*
Zanidip® (lercanidipine) and Zanipress® (lercanidipine+enalapril)[1]	**57.7**	54.6	*5.8*
Eligard® (leuprorelin acetate)	**33.0**	33.5	*(1.5)*
Seloken®/Seloken® ZOK/Logimax® (metoprolol/metoprolol+felodipine)	**28.2**	26.3	*7.3*
Avodart® (dutasteride) and Combodart®/Duodart® (dutasteride/tamsulosin)[2]	**24.5**	27.5	*(10.6)*
Urorec® (silodosin)	**23.1**	19.6	*17.4*
Livazo® (pitavastatin)	**14.9**	14.4	*3.4*
Rare Diseases	**254.8**	197.5	*29.0*
Isturisa® (osilodrostat)	**55.0**	46.0	*19.7*
Signifor® (pasireotide)	**32.4**	28.1	*15.3*
Qarziba® (dinutuximab beta)	**37.6**	36.7	*2.5*
Sylvant® (siltuximab)	**22.4**	18.4	*21.5*
Enjaymo® (sutimlimab)	**31.9**	-	*n.a.*

1) of which Zanidip® € 50.0 million in Q1 2025 and € 46.5 million in Q1 2024
2) Trademarks are owned by or licensed to the GSK group of companies
3) Includes the OTC corporate products for an amount of € 39.1 million in Q1 2025 and € 37.5 million in Q1 2024; Total OTC € 101.8 million in Q1 2025 and € 95.5 million in Q1 2024

Q1 2025 RESULTS BY OPERATING SEGMENTS

Total Revenue Q1 2025



EBITDA[1] Q1 2025



Margin on Revenue:
Rare Diseases: EBITDA[1] 44.0%
Specialty and Primary Care: EBITDA[1] 37.2%

1) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3

Q1 2025 RESULTS – ADJUSTING ITEMS

Reconciliation of Net income to EBITDA[1]

(million Euro)	Q1 2025	Q1 2024	Change %
Net Income	**125.0**	**123.6**	***1.2***
Income Taxes	39.8	37.6	
Financial (income)/expenses, net	30.9	25.8	
o/w net FX (gains)/losses[2]	1.8	2.7	
o/w net monetary (gains)/losses from application of IAS 29	2.0	3.2	
Non-recurring expenses	1.1	0.8	
Non-cash charges from PPA inventory uplift	22.4	14.3	
Adjusted Operating Income[3]	**219.2**	**202.0**	***8.5***
Depreciation, amortization and write downs	50.9	42.0	
EBITDA[1]	**270.2**	**244.0**	***10.7***

Reconciliation of Reported Net income to Adjusted Net income[4]

(million Euro)	Q1 2025	Q1 2024	Change %
Net income	**125.0**	**123.6**	***1.2***
Net monetary (gains)/losses (IAS 29)	2.0	3.2	
Non-recurring expenses	1.1	0.8	
Non-cash charges from PPA inventory uplift	22.4	14.3	
Amortization and write-downs of intangible assets (exc. software)	41.0	34.0	
Tax effects	(16.1)	(12.3)	
Adjusted Net income[4]	**175.5**	**163.7**	***7.2***

Summary of key items

- **FX losses of € 1.8 million** in Q1 2025 vs € 2.7 million losses in Q1 2024
- **Net monetary losses of € 2.0 million** from application of IAS 29 in Q1 2025, vs € 3.2 million losses in Q1 2024
- **Non-recurring costs of € 1.1 million** vs € 0.8 million in Q1 2024
- **Non-cash charges** at the level of gross margin arising from the unwind of the fair value step up of **acquired Rare Diseases inventory**: **€ 22.4 million in Q1 2025** (including € 21.4 million for Enjaymo®) vs. € 14.3 million in Q1 2024 (relating to Qarziba® and Sylvant®)
- **D&A and write downs of assets: increase of € 8.9 million,** of which € 8.7 million from Enjaymo®

1) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3
2) FX losses and FX driven consolidation adjustments
3) Net income before income taxes, financial income and expenses, non-recurring items, and non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3
4) Net income excluding amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3 , monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.

OPPORTUNITY TO MORE THAN DOUBLE SALES OF KEY RARE DISEASES GROWTH DRIVERS

	PRODUCT	2024 REVENUE (€ M)	*Peak Year Sales (PYS) targets (€ M)*
ENDO	Isturisa (osilodrostat)	204	550 – 650 (1)
ENDO	Signifor (pasireotide)	118	150 – 200
ENDO		322	~700 – 850
HEMA-ONCO	Qarziba (Dinutuximab beta)	227	300 – 350
HEMA-ONCO	sylvant (siltuximab)		
HEMA-ONCO	Enjaymo (sutimlimab-jome)	116	250 – 300
HEMA-ONCO		343	~550 – 650

Future growth drivers

- Favorable **market dynamics** (increasing treatment rates)
- **Cushing syndrome label in US**
- **Potential extension of US exclusivity to 2033** (from 2031)(2)
- Successful national reimbursement in **China**

- Opportunity to move up treatment paradigm in **Acromegaly**
- Potential new indication: **Post-Bariatric Hypoglycemia** (PBH); **additional € 150M opportunity** (not included in PYS, enrollment completion by mid-2025)

- Broader penetration in **EU**
- **US approval** for relapsed/refractory patients (included in PYS, FDA meeting to discuss further clinical data analysis mid-2025)
- Potential new indication: **Ewing sarcoma** (not included in PYS, clinical study expected to initiate in H1 2025)

- Significant scope for **improved awareness and diagnosis**

- Evaluate potential **new indications** (not included in PYS) such as **immune thrombocytopenic purpura** (ITP) and geographic expansion

1) Previous PYS target: €500-600 million
2) LOE U.S.: 2031 (2033 pending patent term extensions), last Orange Book patents expire 2035

MULTIPLE LIFECYCLE MANAGEMENT PROGRAMS TO DRIVE GROWTH BEYOND 2027

	PROGRAM	UPCOMING MILESTONE
Osilodrostat Isturisa	• Cushing's syndrome U.S.	Expanded label granted by FDA in April 2025
Pasireotide Signifor	• Post-Bariatric Hypoglycaemia (PBH)	Phase 2 enrollment completion by mid 2025
Dinutuximab beta Qarziba®	• High Risk relapsed/refractory Neuroblastoma U.S.	Meeting with the FDA to discuss further analysis of clinical data expected in mid-2025
	• Ewing sarcoma	Clinical trial to investigate the safety, dose and early signs of effect expected to initiate in H1 2025

Legend

ENDO ***HEMA-ONCO***

Note: Filing dates planning estimates, subject to study read outs and regulatory feedback

19

COMPANY DECLARATIONS, DISCLAIMERS AND PROFILE

Statements contained in this presentation, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable by Management. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control.

These risks and uncertainties include among other things, the uncertainties inherent in pharmaceutical marketing and development, impact of decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug or biological application that may be filed as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of our products, the future approval and commercial success of therapeutic alternatives, Recordati's ability to benefit from external growth opportunities, to complete capital markets or other transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and capital market conditions, cost containment initiatives by payors of medicines and subsequent changes thereto, and the impact that pandemics, political disruption or armed conflicts or other global crises may have on our business.

Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

Recordati (Reuters RECI.MI, Bloomberg REC IM) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care and rare diseases. We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege. We want to support people in unlocking the full potential of their lives. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialization and licensing. Established in 1926, Recordati operates in approximately 150 countries across EMEA, Americas and APAC regions. At the end of 2023, Recordati employed over 4,450 people and consolidated revenue of € 2,082.3 million. For more information, please visit www.recordati.com

DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY'S FINANCIAL REPORTS

The manager responsible for preparing the company's financial reports Niccolo Giovannini declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finance, that the accounting information contained in this presentation corresponds to the document results, books and accounting records.

Offices:
Recordati S.p.A.
Via M. Civitali 1
20148 Milano, Italy

Investor Relations:
Eugenia Litz
+44 7824 394 750
Eugenia.Litz@recordati.com

Investor Relations:
Gianluca Saletta
+39 348 9794876
saletta.g@recordati.it

Website:
www.recordati.com

Our purpose:

Unlocking the full potential of life.

RECORDATI